PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of heartHeartVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Heart. 2007 September; 93(9): 1026–1033.
PMCID: PMC1955008

Renin: friend or foe?

Abstract

Renin maintains blood pressure through vasoconstriction when there is inadequate salt to maintain volume. In populations where blood pressure is more often high than low, and vascular death more common than haemorrhage or dehydration, therapeutic reductions in renin secretion or response are valuable. Whether long‐term benefits are due entirely to blood pressure reduction remains unproved. The pathway can be blocked at its rate‐limiting step (β blockade or direct renin inhibition), the synthesis of the active product, angiotensin II, or at the receptor for angiotensin. Because renin and sodium are the two main factors in blood pressure control, and renin levels vary inversely with sodium load, blood pressure control requires a combination of natriuresis and blocking the consequential increase in renin activity. Being a large and stable molecule, renin is among the easiest and cheapest of hormone measurements. Understanding the simple biochemistry and physiology of renin permits optimal use of the drugs acting to raise or suppress this hormone.

The renin–angiotensin–aldosterone system (RAS) has a central role in acute and chronic regulation of blood pressure (BP). Without renin, blood pressure cannot be protected in the face of sodium depletion.1 Conversely, in the face of salt loss, excess renin production serves only to maintain, not to increase blood pressure.2,3 It is in salt‐replete humans that renin may be undesirable and contribute both to hypertension and end‐organ damage.4,5,6 Several classes of drugs have therefore been developed which confer benefit by blocking the effects of renin. Their proven roles are reducing mortality in heart failure and lowering blood pressure in hypertension. Although they also protect against many complications of hypertension, diabetes, vascular and renal disease, critical analysis is required to discern benefits additional to those of blood pressure reduction.

In heart failure, where the physiological compensations can be more harmful than the fall in cardiac output which elicits the compensation, RAS blockade was one of the stunning successes of 20th century medicine. In hypertension, by contrast, RAS blockade has not clearly performed better than other classes of antihypertensive drugs in protecting against the major complications of stroke, coronary heart disease, and (surprisingly) heart failure.7 This failure can be attributed to the over‐riding importance of blood pressure reduction in protecting against complications of hypertension, and to the need for both components of hypertension—salt and renin—to be targeted for blood pressure control to be achieved in most patients.8 The lesson from heart failure is that the maximum potential of RAS blockade is reaped only when all components of the system are fully blocked in patients in whom RAS would otherwise be maximally activated.9 This review will describe how this objective can be met in hypertension through an understanding of how RAS responds to physiological and pharmacological manipulation; and illustrate how renin measurements help find the correct drug regimen. Finally, this analysis will permit resolution, or at least explanation, of the controversy surrounding the role of RAS blockade in high‐risk patients without overt hypertension or heart failure.

RAS: the main players

Renin is an enzyme secreted from specialised cells in the afferent arteriole of the glomerulus—the “juxtaglomerular apparatus” (JGA). Its circulating substrate, synthesised in the liver, is the protein angiotensinogen, from which renin generates the decapeptide angiotensin I (Ang I). Ang I is in turn converted to the octapeptide Ang II by angiotensin‐converting enzyme (ACE) (fig 1A1A).). Ang II is the principal effector molecule of the RAS, whose main actions are to stimulate the AT1 receptor on arteries and the adrenal cortex to cause vasoconstriction and stimulation of aldosterone secretion. The AT1 receptor also facilitates noradrenaline release from sympathetic nerves, and has chronic trophic actions promoting growth of muscle cells in the heart and arteries.4,5,6 In addition to the classical pathway leading to Ang II and stimulation of the AT1 receptor, smaller biologically active angiotensin peptides can be formed from Ang I and II, especially when levels of the former are increased during treatment with ACE inhibitors and angiotensin receptor blockers (ARBs).10 Whereas Ang(2–8) and Ang(3–8) (Ang III and IV) bind to the AT1 receptors and have similar effects as Ang II, Ang(1–7) binds to the AT2 receptor and stimulates natriuresis and vasodilatation.11,12 The role of the AT2 receptor in adult tissue, however, remains uncertain, being mainly linked to apoptosis of developing tissues during embryogenesis.13,14

figure ht107706.f1
Figure 1 (A) Components of the renin–angiotensin–aldosterone system. (B) The four regulators of renin secretion. JGA, juxtaglomerular apparatus.

Factors controlling renin release

Renin secretion from the JGA in the kidney is regulated by four mechanisms: arterial BP, sympathetic nervous system activity, sodium balance and negative feedback regulation by Ang II (fig 1B1B).15 Interestingly the four major antihypertensive drug classes all cause changes in plasma renin, through one each of these mechanisms.

Pressure16: The unusual site of the JGA endocrine secretory cells around arterioles is testament to the importance of pressure sensing in renin regulation. Renovascular hypertension is the classic example of increased renin secretion due to low pressure at the JGA, which senses the post‐stenotic pressure and “thinks” that systemic pressure needs to be increased. Renal hypoperfusion in heart failure and hypovolaemic states is responsible for the hyper‐reninaemia and consequent secondary hyperaldosteronism in these conditions. Calcium channel blockers (CCBs) and α blockers increase renin partially through their reduction in afferent arteriolar pressure.

Sympathetic stimulation17: This is responsible for the two‐ to threefold increase in renin on standing and exercise, and (through their activation of the baroreceptor) for part of the increase of CCBs and α blockade. The adrenergic receptor on the JGA is the β1 adrenoceptor—one of the few extracardiac sites of the β1‐subtype—and is coupled to cyclic AMP production, through a specific isoform of adenylate cyclase (type 6).18 In hypertension, the β blockers work entirely through blockade of renin secretion.19,20 Side effects due to reduction in cardiac output can be minimised by using the most β1‐selective agents and doses.

Sodium balance21: The macula densa cells in the distal renal tubule sense the Na+ flux through the furosemide‐sensitive Na+K+2Cl transporter. The macula densa is a discrete region of specialised columnar epithelial cells at the point of the renal distal tubule, which lies adjacent to the JGA in the afferent arteriole. Prostaglandins and adenosine act as signals from the macula densa to the JGA, respectively stimulating and inhibiting renin release.21

At steady state—that is, when there has been no recent change in sodium intake or output—Na+ flux at the macula densa is largely a measure of salt intake. Hence the concept of renin–sodium profiles (fig 22),), and the major role of dietary salt in determining plasma renin in healthy people.19 However, the fascinating and clinically important feature of this mechanism is that when Na+ handling is perturbed either pharmacologically or pathologically, the Na+ flux through the Na+K+2Cl transporter and consequent effect upon renin secretion remain altered until the perturbation is removed or corrected. For this reason, as discussed below, measurement of a low plasma renin has become an invaluable method of detecting patients in whom Na+ retention is present owing to causes such as age‐related nephron loss,22 primary hyperaldosteronism (Conn syndrome),23 genetic gain of function in a Na+ channel,24 or the ingestion of excess salt or a drug which reduces Na+ excretion.25 The non‐steroidal anti‐inflammatory drugs illustrate this last category. Of most practical import, the increase in renin secretion seen with diuretics is due to reduced Na+ delivery to the macula densa,26 so that renin measurement allows accurate titration and choice of dose and type of diuretic in patients with resistant hypertension.

figure ht107706.f2
Figure 2 Definition of high, medium, and low renin by renin–sodium profiling.19 Reprinted with permission from Brunner HR, Laragh JH, Baer L, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972;286:441–9. ...

Negative feedback regulation by Ang II27: The major tonic regulator of renin secretion is through negative feedback regulation by Ang II. Ang II acts via AT1 receptors on the juxtaglomerular cells to inhibit the release of renin, thus reducing plasma renin activity (PRA) and the production of Ang I and Ang II. Although first recognised in the 1960s, it was only the advent of chronic RAS blockade by ACE inhibitors which led to recognition of the physiological importance of Ang feedback. In most people, ACE inhibitors or ARBs lead to several‐fold increases in plasma renin.28

The four regulators of renin secretion can amplify or cancel each other. However, most patients receiving β blockade have a low plasma renin, even if also receiving an ACE inhibitor (ACEi) or ARB.29 The patients whose PRA remains suppressed despite receiving multiple drugs which stimulate renin secretion must have Na+‐dependent hypertension; this recognition has been invaluable in detecting interesting secondary causes, and in tailoring medical treatment of resistant hypertension.

Age and ethnicity

Sodium balance is the main chronic determinant of individual plasma renin values, leading to considerable interest in surrogates for detecting patients with low renin.30 Of these surrogates, the main are age and ethnic group. Plasma renin falls by 17% each decade.31,32,33 Ethnic variation in renin distribution is also recognised, and in particular younger black subjects have lower levels than Caucasians.34 There is little doubt that genetic variation in Na+ handling is the main reason, but none of the genes or alleles has yet been clearly identified; the mechanisms could vary from anatomical variation in nephron number or size to molecular regulation of renal Na+ channels.

Although the age and ethnic variation in mean renin levels is striking, it is important to emphasise individual variation35,36; no sudden transition to low‐renin hypertension occurs once patients enter their later 50s and 60s. Now that we recognise the importance of determining a patient's place in the spectrum of plasma renin in order to rationalise treatment, there is a case for measuring rather than guessing the renin level from the surrogates of age and race. As will be discussed, renin measurement may be especially helpful in treated patients, where the effects of treatment move patients across the spectrum.

Measuring renin system activity

Terminology

“Renin activity” measures the capacity of renin to generate Ang I. “Renin mass” refers to the amount or concentration of renin (not including its precursor, prorenin) in the plasma. “Active renin” was formerly used to describe the amount of renin in the plasma.

Renin assays

PRA assays measure by competitive radioimmunoassay the amount of Ang I generated in a 1 hour incubation of plasma.37 The enzymatic amplification generates a sensitive assay, but at the expense of the labour required to measure each sample with and without the hour's incubation. When PRA is low, there is little amplification, and the log‐normal distribution of renin means that a disproportionate number of samples are below detection limits.29 Because the assay relies on the presence in plasma of saturating levels of renin substrate (ie, angiotensinogen), very high renin levels can be underestimated as a result of substrate exhaustion before the hour's incubation is complete.

Renin mass is measured by a two‐site (or “sandwich”) assay.38,39 An immobilised antibody that binds both renin and prorenin is used to capture enzyme from the sample. Renin is then measured using a second, labelled antibody specific to renin. Chemiluminescent labelling has enabled cheap, high‐throughput and highly sensitive ELISA plate assays, which extend the limits for renin detection at both ends of the range.

The observation, with the newer assays, that renin concentration varies up to 1000‐fold between subjects, compared with the trivial two‐ to threefold within‐subject changes with posture and exercise, supports a more important chronic rather than acute role for renin (the reverse is probably true of the sympathetic system). The observation also has a valuable practical import, telling us that random outpatient samples from seated patients are perfectly adequate for detecting patients with abnormal values at either end of the range.29 In other words, we can distinguish the patient with “high renin” and “low renin” without bringing them into hospital, as used to be taught, for a night of rest before sampling! Moreover, renin is stable in blood for several hours, provided that the sample is not chilled (to avoid cryoactivation of the prorenin to give spuriously high renin values).40,41

Clinical relevance of plasma renin measurements

Because of the textbook teaching that accurate renin assessment required admission to hospital, and the expense of older assays, renin measurements have typically been reserved for research or specialist investigation. The principal clinical value of renin measurement, historically, has been the recognition of patients at the upper and lower extremes of the distribution who may have secondary causes of hypertension—particularly renal artery stenosis (high renin) and primary hyperaldosteronism (Conn syndrome: low renin). A less well known use of renin measurement is in the assessment of patients with low blood pressure. Here the initial differential usually lies between an autonomic neuropathy, where loss of sympathetic innervation of the JGA β1 receptor leads to profound renin suppression, and Na+ depletion, where a combination of macula densa and adrenergic stimulation causes a marked increase in renin levels.

Renin measurements have also been of interest in epidemiology, where the recently confirmed evidence that high renin is an independent risk factor for myocardial infarction led to placebo‐controlled trials like HOPE investigating the benefit of RAS blockade in high‐risk patients, and to the hypothesis of benefits from RAS blockade “beyond blood pressure control”.36,42,43 To date, the complexity of the older renin assays has limited the number and size of epidemiological studies measuring renin, with the consequence that its predictive value in individual patients remains controversial and probably small.43,44 The high‐throughput renin mass assay provides an opportunity for incorporating measurements into adequately powered prospective studies.

However, the main large‐scale clinical potential of automated renin assays is in the rationalisation of drug treatment for hypertension, as well as more efficient detection of patients with secondary causes. Samples taken from a patient seated for 10–15 minutes are adequate for interpretation. It is generally unnecessary to change treatment, provided that the effects of drugs are borne in mind, as summarised below. Although blood samples for renin can be taken in the primary care setting—and we ourselves conduct much of our research there,29 and routinely request renin sampling before patients' first clinic visit—renin should probably remain a specialist measurement until there is good evidence of benefit from more widespread use.

Influence of treatment on plasma renin and other components of RAS

All drugs in use for hypertension have an influence on plasma renin and other components of RAS (fig 33).29,45 In the case of “B, C, D” drugs, the change in plasma renin reflects the change in overall RAS activity—suppressed by β blockers (“B”), activated by CCBs (“C”') and diuretics (“D”) in compensation for their reduction of BP and Na+ excess. The “A” drugs, by contrast, act like “B” to suppress RAS, but cause an increase in renin secretion by blocking the negative feedback of Ang II upon renin (table 11).). Whether this increase in renin and consequently Ang I levels can lead to escape from ACE inhibitors and/or ARBs remains uncertain. Interestingly, the increase in renin mass is probably the best “downstream” measurement of the RAS pathway because the more effective the blockade, the greater the loss of negative feedback. Plasma renin rises more on treatment with a combination of an ACE inhibitor and an ARB than with either alone, indicating that neither alone is maximal.28 The recently introduced class of direct renin inhibitor (DRI) also blocks the negative feedback, but causes a dissociation between the rise in renin mass and reduction in renin activity (table 11).46 Plasma levels of Ang (both I and II) fall on β blocker and DRI treatment,46,47 whereas they are dissociated on ACEi treatment (high Ang I, low Ang II) and increased on ARB treatment. Aldosterone is a variable downstream marker of RAS activity, because even slight increases of its major secretagogue, K+, can over‐ride the expected reduction owing to RAS blockade.

figure ht107706.f3
Figure 3 Effects of the main classes of antihypertensive drugs upon the renin–angiotensin system.
Table thumbnail
Table 1 Impact of different classes of antihypertensive agent on renin mass and plasma renin activity

How to select treatments: impact of renin upon current guidelines

That hypertension must be due to either or both of excess vasoconstriction and volume is as incontrovertible as the law of physics—Poiseuille's lawi—from which the assertion is derived. That renin is the major chronic vasoconstrictor was suggested long ago, but remains a conjecture based on the difficulty of maintaining blood pressure during salt depletion after RAS blockade, and the absence of new vasoconstrictor candidates from the genome project. That all successful drugs for hypertension work primarily through either RAS blockade or Na+ elimination is also still a theory, based partly on studies comparing the same patient's response to the major drugs, and partly on the failure of drugs blocking alternative pathways (eg, the sympathetic) to achieve similar efficacy in BP reduction.

The concept of two types of hypertension, each with their preferred initial treatment, is now enshrined in the NICE and BHS treatment guidelines.48 (fig 4A4A).). Based on the original AB/CD algorithm,20 these recommend “A” (exceptionally “B”) for younger Caucasians, and “C” or “D” for all others. However, the guidelines also recognise that most patients should have a combination of the two pairs, given that most patients do not lie at the extremes of plasma renin, and need both vasoconstriction and volume components to be blocked. Recent outcome trials have, indeed, reported an average of more than two drugs per patient once target BP is achieved. At present all guidelines, except the American (JNC 7)49 recommend initial treatment with monotherapy. But the failure of the less well controlled BP in one arm of the VALUE50 and ASCOT51 studies to “catch up”, despite more add‐on treatment eventually being used in that arm, has raised the interesting possibility that monotherapy stimulates overcompensation, from the component of hypertension that is not blocked (vasoconstriction or Na+ retention). Studies are planned, therefore, to determine the idea that initial combination therapy should be the norm in most patients.52

figure ht107706.f4
Figure 4 Treatment algorithms based on recognition of renin and Na+ as the two key players in hypertension. (A) The NICE/BHS Guideline.49 This is based on the original AB/CD rule,20 but β blockade is dropped as a first‐line ...

Treatment guidelines: evidence and details

Evidence for the AB/CD approach came initially from two crossover studies, which examined the effects of multiple antihypertensive treatments in younger patients (<55 years) rotated through the main classes of antihypertensive agents: ACE inhibitor (A), β blocker (B), CCB (C) and diuretic (D).20,53 Patients were almost twice as responsive to ACE inhibitors or β blocker treatment as to a CCB or diuretic. The exceptions were either in the oldest patient quartile or those who had the lowest PRA, consistent with previous studies.54,55 In both crossover studies, the correlation between responses to the different pairs of treatments was only strong between A and B (ie, patients who responded to A also responded to B), and between C and D. Small crossover studies do not usually influence NICE guidelines. However, AB/CD correctly predicted the poorer BP control, and therefore outcome, in older patients receiving an “AB” drug in each of VALUE, ASCOT and ALLHAT.50,51,56

The main difference between the NICE/BHS 2006 guideline and the original AB/CD rule is the demotion of “B” to special indications. This was a response to the higher stroke rates with atenolol treatment in recent trials, particularly when compared with “A” in the LIFE study.57 Interestingly, this unexpected result may also be explained by one of the crossover studies, which reported a threefold increase in both augmentation index—the now popular measure of arterial wave reflection from a stiffened aorta—and plasma B‐type natriuretic peptide during β blocker treatment.58,59 This adverse effect was confirmed in the atenolol group of the CAFE substudy of ASCOT.60 The diabetogenic effect of “B” has also been blamed, but the similar effect of thiazides is less clearly harmful, and the long‐term consequence of new‐onset diabetes in patients receiving “B” or “D” remains to be resolved.

From guidelines to practice

Although the mass of outcome data and their meta‐analysis in hypertension is perhaps unique in medicine, it is ironic that we are left with a smaller choice of first‐line drugs than a decade ago when the studies were planned. If, however, there are only two physiological routes to developing hypertension, it was inevitable that we would eventually recognise only two main categories of drugs. Within these categories we still have some genuine choices to help cope with patients who do not tolerate or respond to the first choices. There are two classes of “A”; and with excellent timing the renin inhibitor class has arrived as a potential replacement for “B”, acting at the rate‐limiting step of RAS, but expected to lack the downsides of “B” owing to extrarenal β blockade.61,62 Within “CD”, we have several classes of diuretics other than thiazides. But the reason why an understanding of the renin system is important, and the availability of cheap measurement so exciting, is that it is now both necessary and possible to adopt an efficient, rational approach to optimising the choice of drug(s) and doses from the two categories of drugs.

If understanding renin helps us to understand the evidence underpinning the guidelines, the understanding is even more important in progressing beyond where NICE/BHS left off because of lack of evidence. Figure 4B4B illustrates, pending further evidence, a strategy of using renin rather than rote to guide treatment choice at any stage in management. Poiseuille's law holds, whether or not a patient has started medication, but the patient's place in the renin spectrum may shift with treatment. For instance, RAS activation by diuretic may convert a volume‐dependent patient to a renin‐dependent patient, in whom a combination of RAS blockers becomes worthwhile. Conversely, the relief of renin‐driven vasoconstriction may reduce pressure natriuresis, and convert a vasoconstricted‐patient to a volume‐dependent patient requiring higher doses of thiazide or combination with other diuretics. In theory, at least, even the most difficult hypertension should yield to a combination of sufficient RAS blockade and diuretic.

Diuretic choice and dose in low‐renin hypertension

Choice of diuretic and dose may sound obvious but this was ignored for years in the development of fixed‐dose combinations of thiazide, usually HCTZ 12.5 mg, with various RAS blockers: β blockers, ACEi and, till recently, ARBs. The view that low‐dose thiazide is maximal came from small parallel‐group studies of untreated, often younger patients (ie, those with high renin).63,64 The older patient, as we have seen, typically has low renin and requires combination treatment. Figure 5A5A shows the dramatic effect of doubling even a 25 mg dose of HCTZ in several hundred patients, aged 55–80, randomly assigned to “C” or “D”. And in a recent crossover study of patients with low renin despite treatment with a CCB, we found that a dose of bendroflumethiazide 5 mg was necessary to achieve the same BP reduction as spironolactone 50 mg or amiloride 20 mg (fig 5B5B).). “The “de‐suppression” of plasma renin by bendroflumethiazide was also dose related, but even at 5 mg bendroflumethiazide was only half as effective as the K+‐sparing diuretics in increasing renin. So in patients with resistant hypertension—uncontrolled despite use of A + C + D—the value of adding spironolactone or amiloride is due partly to natriuresis, but partly also to their renin activation and hence potentiation of the RAS blockade. Currently we use spironolactone only in such resistant patients.29,65,66 For first‐line treatment we use thiazides, sticking to low doses to avoid diabetes, with a “whiff” of amiloride to avoid hypokalaemia.67 Perhaps it would in the future be more logical to use an effective dose of amiloride or spironolactone to avoid diabetes, with a “whiff” of thiazide to avoid hyperkalaemia. Outcome data may be lacking, but we also lack outcome data to support the benefits of thiazides at their currently recommended doses.

figure ht107706.f5
Figure 5 Low‐dose thiazides are not maximal. (A) Comparison of hydrochlorothiazide 25 mg and 50 mg in the INSIGHT Trial.81 A total of 6321 patients with hypertension were randomised, after a month receiving placebo alone, ...

Treatment combinations for patients with high renin, and their titration

Once patients are receiving multiple diuretics and a CCB, they resemble another condition associated with very high renin levels—namely, heart failure—in which a combination of multiple RAS blockers has been shown to be beneficial.9 However, as mentioned earlier, a downstream demonstration of complete RAS blockade is difficult with most of the drugs. Plasma aldosterone is affected by small rises in K+, and plasma Ang II is either unmeasurable or unmeaningful after ACEi or ARB treatment, respectively. Dose‐related changes in renin activity or Ang II can be demonstrated after β blockade or DRI, and show that the latter reduces PRA even when combined with the drugs that normally increase PRA.68

Key points

  • The main physiological role of the renin–angiotensin system (RAS) is to protect against Na+ loss, and the hypotension which results. When inappropriately high for the level of Na+ in the body, renin production can contribute to hypertension and end‐organ damage.
  • Renin secretion is regulated by four mechanisms: arterial pressure, sympathetic nervous system activity, salt intake and negative feedback regulation by Ang II.
  • Most antihypertensive drugs influence the measurement of plasma renin activity (PRA), acting on one of the above mechanisms. ACE inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers and diuretics increase PRA, whereas β blockers and renin inhibitors reduce PRA.
  • At the population level, PRA is negatively correlated with age and Na+ intake, and therefore also with blood pressure (BP). In many patients with hypertension, however, PRA is inappropriately high for the level of Na+ intake, and limits the effectiveness of drugs used to eliminate Na+.
  • In hypertension, therefore, it is rational to combine drugs which, respectively, eliminate Na+ and block the RAS. Combination treatment is likely to become routine even for initial treatment of most patients, and will improve rates of BP control.
  • In high‐renin states—namely heart failure, strategies to increase RAS suppression (eg, ACE inhibitor/ARB combination therapy) can improve treatment outcomes. In other conditions, benefits are proportional to the prior contribution of renin to a patient's hypertension or other cardiovascular risk.
  • Measurement of renin is now straightforward. In addition to diagnosis of secondary causes of hypertension, the measurement permits recognition and titration of the patient with low renin in whom extra diuretic is required to de‐suppress renin secretion and potentiate further RAS blockade.

Tissue renin

This article has concentrated on circulating renin because it is measurable and explains most of the observed effects of the drug classes discussed. Local production within the heart, arteries and kidneys is likely, but its importance is much harder to ascertain than that of circulating renin.15 That may change with the discovery of a “renin receptor” in these tissues, which binds both renin and its precursor, prorenin, causing non‐proteolytic activation of renin system activity with production of Ang I and the activation of intracellular mitogen‐activated protein kinases, ERK1 and ERK2, independently of angiotensin production.69,70 Blockade of the non‐proteolytic activation of prorenin by a decoy peptide inhibits the development of left ventricular fibrosis and hypertrophy in stroke‐prone spontaneously hypertensive rats.71 These are early and exciting days in our unravelling of the renin receptor, and determination of whether it provides another target to be considered in achieving full RAS blockade.

Benefits beyond BP control?

One of the reasons for interest in tissue renin is as an explanation for the still controversial notion that RAS blockade confers outcome benefits not explained by BP reduction alone.72 This seems most widely accepted, if still not completely proved, in the treatment of diabetes and some other nephropathies, with some evidence also for benefit of combined RAS blockade to reduce proteinuria.73 For more major complications of hypertension, the most up to date retrospective meta‐regression analysis of data from almost 150 000 patients provides some encouragement, reporting that ACE inhibitors achieve BP‐independent reduction in the relative risk of coronary heart disease of about 9% (95% CI 3 to 14%).74 In trying to dissect this observation, it is tantalising that in support of the strictest interpretation of the hypothesis, a number of ACE inhibitors have demonstrated outcome benefit for patients with controlled blood pressure, despite blood pressure falls of <5 mm Hg.42,75,76 In similar normotensive populations, calcium blockers have not achieved benefit76; and meta‐analysis of “more versus less” BP lowering in uncontrolled hypertension shows benefit of “intensive” BP control only in patients with diabetes.77 But in prospective analyses the RAS hypothesis remains not so much unproved, as untested, because of the failure closely to match BP between groups.74,78,79,80 As this article has now explained, the failure was inevitable because of the age‐related fall in renin, and change in pattern of BP response. To test the RAS hypothesis, renin needs first to be de‐suppressed by “C” or “D”, as now recommended for first‐line treatment of older hypertensive patients,48 and a pilot study conducted to match BP on the selected RAS‐blocking and non‐blocking regimens.

Conclusion

So, renin: friend or foe? Given the number of drug classes we employ to block renin, it is certainly seen mainly as foe. For middle‐aged and older populations eating Western diets rich in salt and fat, renin may indeed be at best unnecessary and at worst harmful. Yet in the contest between renin and Na+ which, as this article has explained, underpins hypertension, it is Na+ which wins in Western society, leading to suppression of renin secretion from ageing kidneys. So when it came to the large outcome trials in older hypertensive patients comparing drugs which targeted renin or Na+ as their primary mode of action, the latter have generally outperformed simply by lowering BP more effectively.

These trials teach us that we should use renin as a friend in order to reap maximum benefit from RAS blockade. This means rendering hypertension renin‐dependent by optimal use of diuretics, and by measuring renin to help determine when more diuretic or more RAS blockade is required. Despite considerable progress in the past decade, most patients with hypertension have failed to achieve target BP, and we have failed to ascertain the true benefits of renin blockade. Rational understanding and exploitation of the renin–salt interaction allows these failures in the clinic and research to be reversed.

Abbreviations

ACEi - ACE inhibitor

Ang I (II) - angiotensin I (II)

ARBs - angiotensin receptor blockers

BP - blood pressure

CCBs - calcium channel blockers

DRI - direct renin inhibitor

JGA - juxtaglomerular apparatus

PRA - plasma renin activity

RAS - renin–angiotensin–aldosterone system

Footnotes

iJean‐Louis Marie Poiseuille (1799–1869): Laminar flow down a rigid tube is proportional to the pressure difference between the ends. Better known to cardiologists for his subsequent recognition that the proportionality constant includes the tube's radius raised to the fourth power: R  = πr4p/8ηl

Funding: The British Heart Foundation provided programme grant support to the author but were not involved in the writing of the review or the decision to submit the manuscript for publication.

Competing interests: MJB has been reimbursed by Pfizer, Menarini, Novartis, BMS/Sanofi, MSD, Servier and Bayer for speaking engagements or consulting, or both. The Clinical Pharmacology Unit has received research funds from Menarini, Bayer, Servier and BMS/Sanofi.

References

1. MacGregor G A, Markandu N D, Roulston J E. et al Maintenance of blood pressure by the renin‐angiotensin system in normal man. Nature 1981. 291329–331.331 [PubMed]
2. Cruz D N, Simon D B, Nelson‐Williams C. et al Mutations in the Na‐Cl cotransporter reduce blood pressure in humans. Hypertension 2001. 371458–1464.1464 [PubMed]
3. Simon D B, Nelson Williams C. et al Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide‐sensitive Na‐Cl cotransporter. Nat Genet 1996. 1224–30.30 [PubMed]
4. Weir M R, Dzau V J. The renin‐angiotensin‐aldosterone system: a specific target for hypertension management. Am J Hypertens 1999. 12205–13S.13S
5. Volpe M, Savoia C, De Paolis P. et al The renin‐angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol 2002. 13(Suppl 3)S173–S178.S178 [PubMed]
6. Brewster U C, Setaro J F, Perazella M A. The renin‐angiotensin‐aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003. 32615–24.24 [PubMed]
7. Turnbull F. Effects of different blood‐pressure‐lowering regimens on major cardiovascular events: results of prospectively‐designed overviews of randomised trials. Lancet 2003. 3621527–1535.1535 [PubMed]
8. Laragh J H, Letcher R L, Pickering T G. Renin profiling for diagnosis and treatment of hypertension. JAMA 1979. 241151–156.156 [PubMed]
9. McMurray J J, Ostergren J, Swedberg K. et al Effects of candesartan in patients with chronic heart failure and reduced left‐ventricular systolic function taking angiotensin‐converting‐enzyme inhibitors: the CHARM‐Added trial. Lancet 2003. 362767–771.771 [PubMed]
10. Cesari M, Rossi G P, Pessina A C. Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases. J Hypertens 2002. 20793–799.799 [PubMed]
11. Luque M, Martin P, Martell N. et al Effects of captopril related to increased levels of prostacyclin and angiotensin‐(1–7) in essential hypertension. J Hypertens 1996. 14799–805.805 [PubMed]
12. Walters P E, Gaspari T A, Widdop R E. Angiotensin‐(1–7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 2005. 45960–966.966 [PubMed]
13. Henrion D, Kubis N, Levy B I. Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension 2001. 381150–1157.1157 [PubMed]
14. Li W, Ye Y, Fu B. et al Genetic deletion of AT2 receptor antagonizes angiotensin II‐induced apoptosis in fibroblasts of the mouse embryo. Biochem Biophys Res Commun 1998. 25072–76.76 [PubMed]
15. Persson P B. Renin: origin, secretion and synthesis. J Physiol 2003. 552667–671.671 [PubMed]
16. Finke R, Gross R, Hackenthal E. et al Threshold pressure for the pressure‐dependent renin release in the autoregulating kidney of conscious dogs. Pflugers Arch 1983. 399102–110.110 [PubMed]
17. DiBona G F. Neural control of the kidney: functionally specific renal sympathetic nerve fibers. Am J Physiol Regul Integr Comp Physiol 2000. 279R1517–R1524.R1524 [PubMed]
18. Wang T, Brown M J. Differential expression of adenylyl cyclase subtypes in human cardiovascular system. Mol Cell Endocrinol 2004. 22355–62.62 [PubMed]
19. Brunner H R, Laragh J H, Baer L. et al Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972. 286441–449.449 [PubMed]
20. Dickerson J E C, Hingorani A D, Ashby M J. et al Optimisation of anti‐hypertensive treatment by crossover rotation of four major classes. Lancet 1999. 3532008–2013.2013 [PubMed]
21. Persson A E, Ollerstam A, Liu R. et al Mechanisms for macula densa cell release of renin. Acta Physiol Scand 2004. 181471–474.474 [PubMed]
22. Keller G, Zimmer G, Mall G. et al Nephron number in patients with primary hypertension. N Engl J Med 2003. 348101–108.108 [PubMed]
23. Stewart P M. Mineralocorticoid hypertension. Lancet 1999. 3531341–1347.1347 [PubMed]
24. Shimkets R A, Lifton R P. Recent advances in the molecular genetics of hypertension. Curr Opin Nephrol Hypertens 1996. 5162–165.165 [PubMed]
25. Stichtenoth D O, Marhauer V, Tsikas D. et al Effects of specific COX‐2‐inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. Kidney Int 2005. 682197–2207.2207 [PubMed]
26. Mann B, Hartner A, Jensen B L. et al Furosemide stimulates macula densa cyclooxygenase‐2 expression in rats. Kidney Int 2001. 5962–68.68 [PubMed]
27. Vander A J, Geelhoed G W. Inhibition of renin secretion by angiotensin. II. Proc Soc Exp Biol Med 1965. 120399–403.403 [PubMed]
28. Azizi M, Guyene T T, Chatellier G. et al Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997. 29634–640.640 [PubMed]
29. Hood S, Cannon J, Foo R. et al Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing. Clin Med 2005. 555–60.60 [PubMed]
30. Muntzel M, Drueke T. A comprehensive review of the salt and blood pressure relationship. Am J Hypertens 1992. 51–42S.42S [PubMed]
31. Meade T W, Imeson J D, Gordon D. et al The epidemiology of plasma renin. Clin Sci (Lond) 1983. 64273–280.280 [PubMed]
32. Belmin J, Levy B I, Michel J B. Changes in the renin‐angiotensin‐aldosterone axis in later life. Drugs Aging 1994. 5391–400.400 [PubMed]
33. Tsunoda K, Abe K, Goto T. et al Effect of age on the renin‐angiotensin‐aldosterone system in normal subjects: simultaneous measurement of active and inactive renin, renin substrate, and aldosterone in plasma. J Clin Endocrinol Metab 1986. 62384–389.389 [PubMed]
34. Brown M J. Hypertension and ethnic group. BMJ 2006. 332833–836.836 [PMC free article] [PubMed]
35. Trenkwalder P, James G D, Laragh J H. et al Plasma renin activity and plasma prorenin are not suppressed in hypertensives surviving to old age. Am J Hypertens 1996. 9621–627.627 [PubMed]
36. Alderman M H, Cohen H W, Sealey J E. et al Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004. 171–7.7 [PubMed]
37. Sealey J E, Laragh J H. Renin and prorenin: advances and declines in methodology. Clin Chem 1996. 42993–994.994 [PubMed]
38. Derkx F H, de Bruin R J, van Gool J M. et al Clinical validation of renin monoclonal antibody‐based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity. Clin Chem 1996. 421051–1063.1063 [PubMed]
39. de Bruin R A, Bouhuizen A, Diederich S. et al Validation of a new automated renin assay. Clin Chem 2004. 502111–2116.2116 [PubMed]
40. Wathen L K, Nuorala K W, Wathen M W. Validation of an immunoradiometric assay to measure plasma levels of active renin. J Clin Lab Anal 1991. 5284–292.292 [PubMed]
41. Herkner K, Herkner C, Fink M. Investigation of plasma renin activity under different conditions for drawing and storing of blood sample. Clin Chim Acta 1983. 127131–135.135 [PubMed]
42. Yusuf S, Sleight P, Pogue J. et al Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med 2000. 342145–153.153 [PubMed]
43. Wang T J, Gona P, Larson M G. et al Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006. 3552631–2639.2639 [PubMed]
44. Meade T W, Cooper J A, Peart W S. Plasma renin activity and ischemic heart disease. N Engl J Med 1993. 329616–619.619 [PubMed]
45. Seifarth C, Trenkel S, Schobel H. et al Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol 2002. 57457–465.465
46. Nussberger J, Wuerzner G, Jensen C. et al Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002. 391e–28.28
47. Blumenfeld J D, Sealey J E, Mann S J. et al Beta‐adrenergic receptor blockade as a therapeutic approach for suppressing the renin‐angiotensin‐aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999. 12451–459.459 [PubMed]
48. NICE/BHS CG34 Hypertension ‐ NICE guideline (all the recommendations). http://www.nice.org.uk/guidance/CG34/niceguidance/pdf/English 2006 (accessed 27 May 2007)
49. Chobanian A V, Bakris G L, Black H R. et al The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003. 2892560–2572.2572 [PubMed]
50. Julius S, Kjeldsen S E, Weber M. et al Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004. 3632022–2031.2031 [PubMed]
51. Dahlof B, Sever P S, Poulter N R. et al Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo‐Scandinavian Cardiac Outcomes Trial‐Blood Pressure Lowering Arm (ASCOT‐BPLA): a multicentre randomised controlled trial. Lancet 2005. 366895–906.906 [PubMed]
52. Welsh L, Ferro A. Drug treatment of essential hypertension: the case for initial combination therapy. Int J Clin Pract 2004. 58956–963.963 [PubMed]
53. Deary A, Schumann A, Murfet H. et al Double‐blind, placebo‐controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 2002. 20771–777.777 [PubMed]
54. Materson B J, Reda D J, Cushman W C. et al Single‐drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993. 328914–921.921 [PubMed]
55. Philipp T, Anlauf M, Distler A. et al Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. BMJ 1997. 315154–159.159 [PMC free article] [PubMed]
56. ALLHAT Officers and Coordinators, for the ALLHAT Collaborative Research Group Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT). JAMA 2002. 2882998–3007.3007 [PubMed]
57. Dahlof B, Devereux R B, Kjeldsen S E. et al The Losartan Intervention For Endpoint Reduction in Hypertension Study. Lancet 2002. 359995–1003.1003 [PubMed]
58. Cockcroft J R, Brown M J. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. Lancet 2002. 3592202
59. Deary A J, Schumann A L, Murfet H. et al Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci (Lond) 2002. 103493–499.499 [PubMed]
60. Williams B, Lacy P S, Thom S M. et al Differential impact of blood pressure‐lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006. 1131213–1225.1225 [PubMed]
61. Staessen J A, Li Y, Richart T. Oral renin inhibitors. Lancet 2006. 3681449–1456.1456 [PubMed]
62. Azizi M, Webb R, Nussberger J. et al Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006. 24243–256.256 [PubMed]
63. Carlsen J E, Kober L, Torp‐Pedersen C. et al Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990. 300975–978.978 [PMC free article] [PubMed]
64. Girvin B, Johnston G D. A randomized comparison of a conventional dose, a low dose and alternate‐day dosing of bendrofluazide in hypertensive patients. J Hypertens 1998. 161049–1054.1054 [PubMed]
65. Lim P O, Jung R T, MacDonald T M. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow‐up study. Br J Clin Pharmacol 1999. 48756–760.760 [PMC free article] [PubMed]
66. Calhoun D A, Nishizaka M K, Zaman M A. et al Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002. 40892–896.896 [PubMed]
67. Ramsay L E, Yeo W W, Jackson P R. Diabetes, impaired glucose tolerance and insulin resistance with diuretics. Eur Heart J 1992. 13(Suppl G)68–71.71 [PubMed]
68. O'Brien E, Barton J, Nussberger J. et al Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin‐converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007. 49276–284.284 [PubMed]
69. Nguyen G, Delarue F, Burckle C. et al Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002. 1091417–1427.1427 [PMC free article] [PubMed]
70. Danser A H, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005. 461069–1076.1076 [PubMed]
71. Ichihara A, Kaneshiro Y, Takemitsu T. et al Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006. 47894–900.900 [PubMed]
72. Williams B. The renin angiotensin system and cardiovascular disease: hope or hype? J Renin Angiotensin Aldosterone Syst 2000. 1142–146.146 [PubMed]
73. Mogensen C E, Neldam S, Tikkanen I. et al Randomised controlled trial of dual blockade of renin‐angiotensin system in patients with hypertension, microalbuminuria, and non‐insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000. 3211440–1444.1444 [PMC free article] [PubMed]
74. Turnbull F, Neal B, Pfeffer M, for the Blood Pressure Lowering Treatment Trialists' Collaboration Blood pressure dependent and independent effects of agents that inhibit the renin‐angiotensin system. J Hypertens 2007. 25951–958.958 [PubMed]
75. Fox K M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double‐blind, placebo‐controlled, multicentre trial (the EUROPA study). Lancet 2003. 362782–788.788 [PubMed]
76. Poole‐Wilson P A, Lubsen J, Kirwan B A. et al Effect of long‐acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004. 364849–857.857 [PubMed]
77. Turnbull F, Neal B, Algert C. et al Effects of different blood pressure‐lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005. 1651410–1419.1419 [PubMed]
78. Parving H H, Rossing P. Renoprotective effects of renin‐angiotensin‐system inhibitors. Lancet. 2006;367: 898–9; author reply 900–2,
79. Casas J P, Chua W, Loukogeorgakis S. et al Effect of inhibitors of the renin‐angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta‐analysis. Lancet 2005. 3662026–2033.2033 [PubMed]
80. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002. 8918–25A.25A [PubMed]
81. Brown M J, Palmer C R, Castaigne A. et al Morbidity and mortality in patients randomised to double‐blind treatment with once‐daily calcium channel blockade or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000. 356366–442.442 [PubMed]
82. Hood S J, Taylor K P, Ashby M J. et al The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double‐blind crossover trial in patients with low‐renin hypertension and elevated aldosterone‐renin ratio. Circulation 2007. 116268–275.275 [PubMed]

Articles from Heart are provided here courtesy of BMJ Publishing Group